Log In
BCIQ
Print this Print this
 

GDC-0276, RG7893

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionSelective Nav1.7 (SCN9A) inhibitor
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNav1.7 (SCN9A) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat pain
Regulatory Designation
PartnerRoche;
Xenon Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/16/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today